| Previous Close | 0.1500 |
| Open | 0.1550 |
| Bid | 0.1550 x 0 |
| Ask | 0.1600 x 0 |
| Day's Range | 0.1550 - 0.1550 |
| 52 Week Range | 0.1000 - 0.2600 |
| Volume | 1,000 |
| Avg. Volume | 328,093 |
| Market Cap | 27.268M |
| Beta (5Y Monthly) | 0.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0190 |
| Earnings Date | Apr. 28, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
MedX Health Corp. Announces Non-Brokered Private Placement and Closing of First Tranche
MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) is pleased to announce that it has received Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 13,888,888 units at $0.18 per unit ("Unit"), to raise up to $2,500,000. Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.25, exercisable for a period of two years from the date of issue. Closing of the Placement, which will take place in tranches, will be subject to receipt of subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. Qualified Agents may receive commissions in respect of subscriptions introduced by them by way of cash up to 8% of funds so introduced, and issuance of agent’s warrants ("Agent’s Warrant(s)") equal in number up to 8% of the number of units so subscribed for. Each Agent’s Warrant, which is non-transferable, will be exercisable to acquire one Unit at $0.18 per Unit, at any time during the period of two years following the Closing.
- Business Wire
MedX Health Corp. Names Health-Care Leader Sylvain Desjeans as Chief Revenue Officer
MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) is pleased to announce the appointment of Sylvain Desjeans as Chief Revenue Officer. With more than 30 years of health-care industry experience, Mr. Desjeans is a seasoned leader who has successfully implemented and led large-scale strategic growth plans and global product licensing initiatives for international pharmaceutical and medical companies. He comes to MedX from tenures as Country Manager (Canada) for Aspen Pharmacare and senior leadership positions at Accucaps Industries Limited and Biovail Pharmaceuticals.
- Business Wire
MedX Health Corp. Announces 2020 Year End Results
MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) announced its results for the year ended December 31, 2020, which are also available on SEDAR (www.sedar.com).
